ArticleExpert review of precision medicine and drug development
Use of big data in drug development for precision medicine.
Article in Expert review of precision medicine and drug development. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 36 citations in OpenAlex.
- Big Data for Drug Discovery: Some Historical Landscape, Considerations, and Applications for a Medicinal Chemist.ACS omega · 2026Review
- Exploring the ethical issues posed by AI and big data technologies in drug development.Frontiers in public health · 2025Review
- Exploration of Protein Aggregations in Parkinson's Disease Through Computational Approaches and Big Data Analytics.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Evolving scenario of big data and Artificial Intelligence (AI) in drug discovery.Molecular diversity · 2021Article
- An exploratory assessment of the applicability of direct-to-consumer genetic testing to translational research in Japan.BMC research notes · 2021Article
- "Smart Process" of Medical Innovation: The Synergism Based on Network and Physical Space.International journal of environmental research and public health · 2020Article
- Technical Blossom in Medical Care: The Influence of Big Data Platform on Medical Innovation.International journal of environmental research and public health · 2020Article
- Phenotype-Agnostic Molecular Subtyping of Neurodegenerative Disorders: The Cincinnati Cohort Biomarker Program (CCBP).Frontiers in aging neuroscience · 2020Article
- Relationships Between a History of Abuse, Changes in Body Mass Index, Physical Health, and Self-Reported Depression in Female Bariatric Surgery Patients.Bariatric surgical practice and patient care · 2019Article
- Generic chemoprevention of hepatocellular carcinoma.Annals of the New York Academy of Sciences · 2019Review
- Use of big data in drug development for precision medicine: an update.Expert review of precision medicine and drug development · 2019Article
- Natural Products for Drug Discovery in the 21st Century: Innovations for Novel Drug Discovery.International journal of molecular sciences · 2018Review
- Cell type-specific pharmacological kinase inhibition for cancer chemoprevention.Nanomedicine : nanotechnology, biology, and medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
Abstract
Drug development has been a costly and lengthy process with an extremely low success rate and lack of consideration of individual diversity in drug response and toxicity. Over the past decade, an alternative "big data" approach has been expanding at an unprecedented pace based on the development of electronic databases of chemical substances, disease gene/protein targets, functional readouts, and clinical information covering inter-individual genetic variations and toxicities. This paradigm shift has enabled systematic, high-throughput, and accelerated identification of novel drugs or repurposed indications of existing drugs for pathogenic molecular aberrations specifically present in each individual patient. The exploding interest from the information technology and direct-to-consumer genetic testing industries has been further facilitating the use of big data to achieve personalized Precision Medicine. Here we overview currently available resources and discuss future prospects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.